Dr Michael Potter is a highly experienced haematologist with over 20 years' experience as a specialist consultant in his field and practises at prominent institutions in London. He specialises in stem cell transplantation, chemotherapy, leukaemia, lymphoma, mieloma, myelodysplasia and myeloproliferative disorders and has a special interest in investigating possible blood disorders such as abnormal blood cell or platelet counts.

Dr Michael Potter qualified with a BA/MA from Cambridge University in 1981 and a MB/BS from the London University in 1984. He then undertook his haematology training across the UK and went on to complete a PhD at the University of Bristol on the detection of minimal disease in acute lymphoblastic leukaemia in 1993. He earned his fellowship to the Royal College of Physicians in 2001.

He is head of the transplant programmes at The Royal Marsden and The London Clinic. The transplant programme at The Royal Marsden is the largest programme in the UK, with over 200 transplants being performed annually.

He is also the programme director for the Stem Cell Transplant programme at the London Clinic, which is the only hospital that possesses a fully accredited JACIE unit in the UK. This programme is one of the largest in Europe, collecting approximately 800 annual donor collections.

In his role as a full-time clinician, he treats patient with chemotherapy and new agencies for a wide range of haematological malignancies and other blood conditionings. He works with a vasty experienced multidisciplinary team to provide the best care and advice in terms of diagnosis and treatment.

His personal feedback from patients is outstanding. He is known for communicating with patients in a friendly, clear, honest and empathic manner, as well as providing patients with a positive outlook in difficult times.

Dr Potter is dedicated to research which is centred on improving treatment outcomes for patients and has been widely published in over 160 peer-reviewed journals.

This year Dr Potter, along with his colleagues showcased world-leading blood cancer therapy at Arab Health 2023. Speaking about immunotherapy, Dr Potter states that incredibly, with this therapy doctors ‘can cure otherwise incurable cancer in groups of patients who have essentially run out of treatment options.’ He claims that up to 50 per cent of patients who have received CAR-T cell therapy are now cured.

Dr Potter is part of several medical organisations, including The American Society for Haematology and The European Blood and Marrow Transplant Group. He is an executive member of the British Society for Blood and Marrow Transplantation Blood and Marrow Transplant Group.

Suspected/confirmed cancer diagnosis only to be seen at The Royal Marsden Hospital. GP or hospital referral letter required for appointments. All other diagnoses please enquire via The London Clinic or Mount Alvernia Hospital.

Medical articles from Dr Michael Potter

CAR T-cell therapy: a promising new cancer treatment

Anaemia: causes, symptoms and treatment